Search

Your search keyword '"MESH: Drug Tolerance"' showing total 8 results
Start Over Descriptor "MESH: Drug Tolerance" Topic mesh: humans
8 results on '"MESH: Drug Tolerance"'

1. Glutamate decarboxylase-dependent acid resistance in Brucella spp.: distribution and contribution to fitness under extremely acidic conditions

Author

Maria Alessandra Damiano, Daniela Bastianelli, Daniela De Biase, Alessandra Occhialini, Axel Cloeckaert, Sascha Al Dahouk, Stephan Köhler, Centre d’études d’Agents Pathogènes et Biotechologies pour la Santé (CPBS), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur, Fondation Cenci Bolognetti - Istituto Pasteur Italia, Fondazione Cenci Bolognetti, Réseau International des Instituts Pasteur (RIIP), Sapienza University [Rome], Bundesinstitut für Risikobewertung - Federal Institute for Risk Assessment (BfR), Institut de Recherche en Infectiologie de Montpellier (IRIM), Infectiologie Santé Publique (ISP-311), Université de Tours-Institut National de la Recherche Agronomique (INRA), This work was supported by grant 1329-485 from the Federal Institute for Risk Assessment, Germany (to A.O. and S.K.), and by funding from Sapienza University of Rome and Fondazione Roma (to D.D.B.). Travels and research stays of A.O., D.D.B., M.A.D., and D.B. were supported by the 2011-2012 Galilée program of Egide (Hubert Curien program), no. 25960UE, from the French and Italian Ministry of Foreign and Europeans Affairs. M.A.D. was a recipient was awarded a postdoctoral fellowship from the foundation Infectiopôle Sud, and A.O. was awarded a Congés pour Recherches ou Conversions Thématiques (CRCT) from Montpellier University, We thank E. Bianchini for her participation in genetic constructions of E. coli strains, B. Saadeh for preliminary GABA tests, C. Göllner for GAD tests, P. Bouhours for preparation of bacterial media, and I. Jacques and D. O'Callaghan for their generous gifts of several marine strains and of B. inopinata BO1 and B. inopinata-like BO2 strains, respectively., Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Infectiologie et Santé Publique (UMR ISP), Institut National de la Recherche Agronomique (INRA)-Université de Tours, and Institut National de la Recherche Agronomique (INRA)-Université de Tours (UT)

Subjects
MESH: Acids/toxicity, Glutamate decarboxylase, MESH: Glutamic Acid/metabolism, Gene Expression, medicine.disease_cause, Applied Microbiology and Biotechnology, MESH: Drug Tolerance, Mice, MESH: Animals, Cloning, Molecular, Brucella inopinata, MESH: Glutamate Decarboxylase/metabolism, MESH: Ochrobactrum/drug effects, 0303 health sciences, Rana catesbeiana, Ecology, biology, Glutamate Decarboxylase, MESH: Brucella/enzymology, Drug Tolerance, Phenotype, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, MESH: Acids/metabolism, Biotechnology, MESH: Gene Expression, Glutamic Acid, Brucella pinnipedialis, MESH: Escherichia coli/genetics, Genetics and Molecular Biology, Brucella, Ochrobactrum, Microbiology, 03 medical and health sciences, medicine, MESH: Brucella/drug effects, Escherichia coli, Animals, Humans, MESH: Cloning, Molecular, extreme acid stress, diagnostic phenotypic trait, glutamate-dependent acid resistance, MESH: Mice, 030304 developmental biology, MESH: Humans, MESH: Ochrobactrum/enzymology, 030306 microbiology, biology.organism_classification, bacterial infections and mycoses, MESH: Rana catesbeiana, Brucella ceti, MESH: Brucella/genetics, MESH: Escherichia coli/metabolism, MESH: Brucella/isolation & purification, Acids, Food Science
Abstract

Brucella is an expanding genus of major zoonotic pathogens, including at least 10 genetically very close species occupying a wide range of niches from soil to wildlife, livestock, and humans. Recently, we have shown that in the new species Brucella microti , the glutamate decarboxylase (Gad)-dependent system (GAD system) contributes to survival at a pH of 2.5 and also to infection in mice by the oral route. In order to study the functionality of the GAD system in the genus Brucella , 47 isolates, representative of all known species and strains of this genus, and 16 strains of the closest neighbor genus, Ochrobactrum , were studied using microbiological, biochemical, and genetic approaches. In agreement with the genome sequences, the GAD system of classical species was not functional, unlike that of most strains of Brucella ceti , Brucella pinnipedialis , and newly described species ( B. microti , Brucella inopinata BO1, B. inopinata -like BO2, and Brucella sp. isolated from bullfrogs). In the presence of glutamate, these species were more acid resistant in vitro than classical terrestrial brucellae. Expression in trans of the gad locus from representative Brucella species in the Escherichia coli MG1655 mutant strain lacking the GAD system restored the acid-resistant phenotype. The highly conserved GAD system of the newly described or atypical Brucella species may play an important role in their adaptation to acidic external and host environments. Furthermore, the GAD phenotype was shown to be a useful diagnostic tool to distinguish these latter Brucella strains from Ochrobactrum and from classical terrestrial pathogenic Brucella species, which are GAD negative.

Published
2014

2. Efficacy of icatibant treatment in patients with hereditary angio-oedema type I resistant to treatment with C1 inhibitor concentrate

Author

Bouillet, L., Boccon-Gibod, I., Dumestre-Perard, C., Cesbron, J. Y., Massot, C., Laboratoire Adaptation et pathogénie des micro-organismes [Grenoble] (LAPM), Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), National Angiodema Reference Centre, Physiopathologie vasculaire : interactions cellulaires, signalisation et vieillissement, Université Joseph Fourier - Grenoble 1 (UJF)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d'immunohistochimie, CHU Grenoble-Hôpital Michallon, Département de Médecine Interne, CHU Grenoble, and Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS)

Subjects
MESH: Adolescent, MESH: Bradykinin, MESH: Humans, MESH: Complement C1 Inhibitor Protein, MESH: Drug Tolerance, MESH: Drug Resistance, MESH: Hereditary Angioedema Types I and II, MESH: Adult, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, MESH: Female, ComputingMilieux_MISCELLANEOUS, MESH: Receptors, Bradykinin
Abstract

International audience

Published
2011

3. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment

Author

Jean-François Delfraissy, Cécile Goujard, François Boué, Thérèse Croughs, Rodolphe Thiébaut, Christine Lacabaratz, Jean-Michel Molina, Yves Levy, Jean-Daniel Lelièvre, Stéphanie Beq, Véronique Avettand-Fenoel, Jean-Paul Viard, Geneviève Chêne, Christine Rouzioux, Laurence Weiss, Michel Morre, Service d'immunologie clinique [Créteil], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Immunologie antivirale systémique et cérébrale, Université Paris-Sud - Paris 11 (UP11)-IFR93-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine interne et maladies infectieuses, Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Immunologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Henri-Mondor Albert-Chenevier, Hôpital Antoine Béclère, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Service de maladies infectieuses et tropicales [Saint-Louis], Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Cythéris, Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Bordeaux Segalen - Bordeaux 2, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Université Paris-Sud - Paris 11 ( UP11 ) -IFR93-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Henri-Mondor Albert-Chenevier, Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut de Santé Publique, d'Epidémiologie et de Développement ( ISPED ), and Guellaen, Georges

Subjects
MESH: CD4 Lymphocyte Count, medicine.medical_treatment, T-Lymphocytes, Cell, MESH : Aged, MESH : Prospective Studies, CD4-CD8 Ratio, HIV Infections, MESH: Cell Cycle, Lymphocyte Activation, MESH: Recombinant Proteins, MESH: HIV-1, 0302 clinical medicine, Prospective Studies, MESH: Aged, 0303 health sciences, MESH: Middle Aged, Cell Cycle, General Medicine, Drug Tolerance, MESH: HIV Infections, MESH : Adult, Cell cycle, Middle Aged, Recombinant Proteins, 3. Good health, medicine.anatomical_structure, MESH: Immunologic Memory, MESH : Lymphopenia, Safety, MESH : HIV-1, Research Article, MESH : Interleukin-7, Adult, MESH : Recombinant Proteins, MESH : Immunologic Memory, T cell, MESH: Drug Tolerance, MESH: Lymphopenia, 03 medical and health sciences, Antigen, Lymphopenia, MESH : Cell Cycle, [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, MESH : CD4 Lymphocyte Count, MESH : HIV Infections, medicine, Humans, MESH : Middle Aged, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, MESH : Safety, MESH: Lymphocyte Activation, [ SDV.BBM ] Life Sciences [q-bio]/Biochemistry, Molecular Biology, MESH : Lymphocyte Activation, 030304 developmental biology, Aged, MESH : T-Lymphocytes, MESH: Humans, business.industry, Interleukin-7, MESH : Humans, MESH: Safety, MESH: Adult, Immunotherapy, medicine.disease, T cell deficiency, MESH: Interleukin-7, MESH: Prospective Studies, CD4 Lymphocyte Count, MESH: T-Lymphocytes, MESH : CD4-CD8 Ratio, MESH : Drug Tolerance, Immunology, HIV-1, MESH: CD4-CD8 Ratio, business, Immunologic Memory, CD8, 030215 immunology
Abstract

International audience; HIV infection results in CD4+ T cell deficiency, but efficient combination antiretroviral therapy (c-ART) restores T cells and decreases morbidity and mortality. However, immune restoration by c-ART remains variable, and prolonged T cell deficiency remains in a substantial proportion of patients. In a prospective open-label phase I/IIa trial, we evaluated the safety and efficacy of administration of the T cell regulator IL-7. The trial included 13 c-ART-treated HIV-infected patients whose CD4+ cell counts were between 100 and 400 cells/microl and plasma HIV RNA levels were less than 50 copies/ml. Patients received a total of 8 subcutaneous injections of 2 different doses of recombinant human IL-7 (rhIL-7; 3 or 10 microg/kg) 3 times per week over a 16-day period. rhIL-7 was well tolerated and induced a sustained increase of naive and central memory CD4+ and CD8+ T cells. In the highest dose group, 4 patients experienced transient increases in viral replication. However, functional assays showed that the expanded T cells responded to HIV antigen by producing IFN-gamma and/or IL-2. In conclusion, in lymphopenic HIV-infected patients, rhIL-7 therapy induced substantial functional and quantitative changes in T cells for 48 weeks. Therefore, patients may benefit from intermittent therapy with IL-7 in combination with c-ART.

Published
2009

4. Tolerability of enteric-coated mycophenolate sodium to 1 year in combination with cyclosporine and corticosteroids in renal transplant recipients

Author

Georges Mourad, Pierre Merville, Lionel Rostaing, Yvon Lebranchu, Peter Lang, Nassim Kamar, Didier Ducloux, François Bayle, M. Kessler, B. Moulin, Michel Delahousse, Valérie Garrigue, Nicole Lefrançois, Bernard Bourbigot, Claire Pouteil-Noble, C. Legendre, Y. Le Meur, Alexandre Karras, François Berthoux, Bernard Charpentier, Kamel Chaouche-Teyara, Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Legendre for The French Myriade FR01 Study Group, Saas, Philippe, Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)

Subjects
Male, MESH: Emulsions, MESH: Tissue Donors, 030232 urology & nephrology, 030230 surgery, Mycophenolate, Gastroenterology, MESH: Cyclosporine, MESH: Kidney Transplantation, 0302 clinical medicine, Adrenal Cortex Hormones, Isoantibodies, Leukopenia, MESH: Middle Aged, Histocompatibility Testing, Drug Tolerance, Middle Aged, Tissue Donors, 3. Good health, Tolerability, Cyclosporine, [SDV.IMM]Life Sciences [q-bio]/Immunology, Drug Therapy, Combination, Emulsions, Female, Kidney Diseases, Tablets, Enteric-Coated, medicine.symptom, medicine.drug, Adult, medicine.medical_specialty, [SDV.IMM] Life Sciences [q-bio]/Immunology, Urinary system, MESH: Drug Tolerance, MESH: Tablets, Enteric-Coated, MESH: Histocompatibility Testing, Mycophenolic acid, MESH: Adrenal Cortex Hormones, 03 medical and health sciences, Internal medicine, medicine, Humans, Adverse effect, MESH: Mycophenolic Acid, Transplantation, MESH: Kidney Diseases, MESH: Humans, business.industry, MESH: Adult, Mycophenolic Acid, Ciclosporin, Kidney Transplantation, MESH: Male, MESH: Isoantibodies, Surgery, MESH: Drug Therapy, Combination, business, MESH: Female
Abstract

International audience; Enteric-coated mycophenolate sodium (EC-MPS) is therapeutically equivalent to mycophenolate mofetil, but delays release of mycophenolic acid until it reaches the small intestine. De novo renal transplant patients taking part in a 12-month, multicenter, randomized study received cyclosporine microemulsion (CsA-ME, early or delayed to day 6), EC-MPS, steroids, and interleukin-2 antagonist induction. Tolerability data relating to EC-MPS are reported. Ninety-seven patients were randomized to early CsA-ME and 100 patients to delayed CsA-ME. Median daily dose of EC-MPS was 1440 mg at all time points throughout the 12-month period. The most frequently reported adverse events were constipation, anemia, urinary tract infection, abdominal pain, leukopenia, and cytomegalovirus infection; there were four malignancies. Fifty patients (24.6%) discontinued EC-MPS prematurely by 12 months, including 42 patients (84%) who discontinued owing to adverse events. No patient discontinued treatment because of gastrointestinal adverse events. Two-thirds of patients (137 [67.5%]) maintained full EC-MPS dose throughout the 12-month study and did not require any dose reduction or dose interruption. EC-MPS is well tolerated in de novo renal transplant recipients when administered in combination with CsA-ME and steroids, with low rates of dose reductions or interruptions. Gastrointestinal adverse events were responsible for dose reduction or interruption in only 5% of patients.

Published
2006

5. RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia

Author

Emilie Laboureyras, Frédéric Simonin, Brigitte L. Kieffer, Jean-Paul Laulin, Marc Parmentier, Audrey Matifas, Jean-Jacques Bourguignon, Catherine Mollereau, David MacTavish, Guy Simonnet, Jack H. Jhamandas, Martine Schmitt, Patrick Laurent, Institut de génétique et biologie moléculaire et cellulaire (IGBMC), Université Louis Pasteur - Strasbourg I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Gilbert-Laustriat : Biomolécules, Biotechnologie, Innovation Thérapeutique, and Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS)

Subjects
Receptors, Neuropeptide, Neuropeptide FF receptor, Adamantane, Blood Pressure, Pharmacology, Ligands, MESH: Analgesics, Opioid, 0302 clinical medicine, MESH: Dipeptides, Heart Rate, Drug tolerance, Chlorocebus aethiops, MESH: Ligands, MESH: Animals, Neuropeptide FF, MESH: Heart Rate, Receptor, 0303 health sciences, Multidisciplinary, Molecular Structure, Chemistry, MESH: Receptors, Neuropeptide, Chronic pain, Sciences du Vivant [q-bio]/Biotechnologies, Dipeptides, Drug Tolerance, MESH: Adamantane, MESH: Blood Pressure, Biological Sciences, MESH: Amides, 3. Good health, Analgesics, Opioid, MESH: COS Cells, Hyperalgesia, COS Cells, MESH: Heroin, medicine.symptom, medicine.drug, MESH: Rats, MESH: Drug Tolerance, MESH: Molecular Structure, 03 medical and health sciences, medicine, Animals, Humans, 030304 developmental biology, MESH: Humans, Antagonist, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, medicine.disease, Amides, MESH: Hyperalgesia, MESH: Cercopithecus aethiops, Rats, Heroin, Opioid, 030217 neurology & neurosurgery
Abstract

International audience; Neuropeptide FF (NPFF) has been proposed to play a role in pain modulation, opioid tolerance, and several other physiological processes. However, pharmacological agents that would help define physiological roles for this peptide are still missing. Here we report the discovery of a potent and selective NPFF receptor antagonist, RF9, that can be administered systemically. This compound does not show any effects by itself but can block efficiently the increase in blood pressure and heart rate evoked by NPFF. When chronically coinjected with heroin, RF9 completely blocks the delayed and long-lasting paradoxical opioid-induced hyperalgesia and prevents the development of associated tolerance. Our data indicate that NPFF receptors are part of a bona fide antiopioid system and that selective antagonists of these receptors could represent useful therapeutic agents for improving the efficacy of opioids in chronic pain treatment.

Published
2006

6. Pain, immunity, opiate and opioid compounds and health

Author

George Stefano, Fricchione, G. L., Goumon, Y., Esch, T., Goumon, Yannick, College at Old Westbury [SUNY] (SUNY Old Westbury), State University of New York (SUNY), Massachusetts General Hospital [Boston], Institut des Neurosciences Cellulaires et Intégratives (INCI), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Physiopathologie du système nerveux., Université Louis Pasteur - Strasbourg I-IFR37-Institut National de la Santé et de la Recherche Médicale (INSERM), and Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]

Subjects
Narcotics, MESH: Protein Precursors, MESH: Sequence Homology, Amino Acid, Substance-Related Disorders, MESH: Drug Tolerance, [SDV]Life Sciences [q-bio], Molecular Sequence Data, Pain, MESH: Amino Acid Sequence, Evolution, Molecular, [SCCO]Cognitive science, MESH: Enkephalins, MESH: Opioid Peptides, Animals, Humans, MESH: Animals, Amino Acid Sequence, Protein Precursors, MESH: Evolution, Molecular, MESH: Humans, MESH: Molecular Sequence Data, Morphine, Sequence Homology, Amino Acid, [SCCO] Cognitive science, Drug Tolerance, Enkephalins, MESH: Narcotics, [SDV] Life Sciences [q-bio], MESH: Morphine, Opioid Peptides, MESH: Substance-Related Disorders, MESH: Pain
Abstract

International audience; We surmise that opioid peptides, i.e., methionine enkephalin, first arose during evolution as modulators of cellular immune function given their immune actions and the presence of enkelytin, a potent antibacterial peptide, and its precursor proenkephalin in animals 500 million years divergent in evolution. Pain probably emerged from this perspective because of its association with proinflammatory events. Endogenous morphine appears to exert positive effects on homeostasis by limiting the degree of excitation. Supporting this view is the fact that the mu3 opiate receptor subtype, which is opioid peptide insensitive and morphine selective, is coupled to constitutive nitric oxide release, which also has this down regulating action in neural, immune, vascular and gastrointestinal tissues. Thus, morphine down regulates immune processes in addiction, an action/function that it appears to normally perform when the situation calls for this action and by so doing in this natural setting, sustains life.

Published
2005

7. [The concept of supersensitivity psychosis. The particular case of clozapine]

Author

Llorca, Pierre-Michel, Penault, F., Lançon, C., Dufumier, E., Vaiva, G., CHU Clermont-Ferrand, Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Laboratoire de Neurosciences Fonctionnelles et Pathologies (LNFP), and Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS)

Subjects
Adult, Male, MESH: Dissociative Disorders, MESH: Psychoses, Substance-Induced, MESH: Humans, MESH: Drug Tolerance, MESH: Substance Withdrawal Syndrome, Catatonia, MESH: Adult, Dissociative Disorders, Drug Tolerance, Psychoses, Substance-Induced, MESH: Male, Substance Withdrawal Syndrome, MESH: Recurrence, Recurrence, MESH: Catatonia, MESH: Psychomotor Disorders, Humans, MESH: Antipsychotic Agents, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Psychomotor Disorders, MESH: Clozapine, Clozapine, Antipsychotic Agents
Abstract

International audience; Neuroleptics are the main biological treatment for psychotic patients. The brutal withdrawal of a neuroleptic treatment may induce an important aggravation of the psychotic symptoms. A few of those relapses may occur very early after the interruption of treatment; they are often associated with a modification of the symptoms and an unfavorable evolution in the course of the illness. Using those clinical observations a few authors have developed the concept of supersensitivity psychosis to explain those kinds of relapses and to formulate hypothesis about tolerance and resistance to neuroleptics. They focus on the possible correlation between supersensitivity psychosis and tardive dyskinesia. We report three cases of a dramatic aggravation of the psychotic symptomatology following the withdrawal of clozapine in three schizophrenic patients resistant to classical neuroleptic treatment. According to the clinical data and to the physiopathological hypothesis, the concept of supersensitivity psychosis can have implications in the therapeutic management of resistant schizophrenic patients.

Published
1999

8. The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients

Author

M. De Lorgeril, Serge Renaud, Jean Ninet, P. Boissonnat, Georges Dureau, René Ferrera, J. Guidollet, Patricia Salen, Salen, Patricia, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Cardioprotection, and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Adult, medicine.medical_specialty, MESH: Hyperlipidemias, Adolescent, medicine.medical_treatment, MESH: Drug Tolerance, 030232 urology & nephrology, Urology, Lipid-lowering agent, Hyperlipidemias, 030204 cardiovascular system & hematology, 030230 surgery, 03 medical and health sciences, 0302 clinical medicine, Fenofibrate, medicine, Humans, Longitudinal Studies, Prospective Studies, MESH: Longitudinal Studies, ComputingMilieux_MISCELLANEOUS, Aged, MESH: Adolescent, MESH: Aged, Transplantation, Chemotherapy, MESH: Humans, MESH: Middle Aged, business.industry, MESH: Heart Transplantation, MESH: Adult, Drug Tolerance, Middle Aged, Lipids, MESH: Lipids, MESH: Prospective Studies, 3. Good health, Surgery, [SDV.AEN] Life Sciences [q-bio]/Food and Nutrition, Heart Transplantation, MESH: Procetofen, Complication, business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, medicine.drug
Abstract

International audience

Published
1994

Catalog

Books, media, physical & digital resources
See catalog results